Clinical efficacy of weekly cisplatin for treatment of patients with breast cancer

  title={Clinical efficacy of weekly cisplatin for treatment of patients with breast cancer},
  author={Ying Ma and N. Zhang and Ning An and Wen-yuan Li and Wei Zhao and Yan-cui Liu},
Abstract Background: We will investigate the efficacy and safety of weekly cisplatin (WC) for treatment of patients with breast cancer (BC) systematically. Methods: This study will describe and critically appraise shared decision approaches used in randomized controlled trials of WC for treatment of patients with BC. We will comprehensively search the following databases: PubMed, EMBASE, Web of Science, Cochrane Library, CINAHL, PsycINFO, Allied and Complementary Medicine Database, Wanfang, and… 
Drug repurposing for anticancer therapies. A lesson from proton pump inhibitors
The authors review the current knowledge regarding the influence of PPIs on the efficacy and safety of cancer chemotherapeutics through the regulation of targets other than the H+/K+-ATPase.
Osthole resensitizes CD133+ hepatocellular carcinoma cells to cisplatin treatment via PTEN/AKT pathway
Combined treatment with osthole can resensitize CD133+ HCC cells to cisplatin treatment via the PTEN/AKT pathway.
Synergistic or Additive Pharmacological Interactions between Magnoflorine and Cisplatin in Human Cancer Cells of Different Histological Origin
Magnoflorine in combination with cisplatin at a fixed ratio of 1:1 augmented their anticancer action and yielded synergistic or additive pharmacological interactions by means of isobolographic method, therefore combined therapy using these two active agents can be a promising chemotherapy regimen in the treatment of some types of breast, lung, rhabdomyosarcoma and glioblastoma cancers.


Preoperative weekly cisplatin, epirubicin, and paclitaxel (PET) improves prognosis in locally advanced breast cancer patients: an update of the Southern Italy Cooperative Oncology Group (SICOG) randomised trial 9908.
The PET weekly regimen significantly improves both DMFS and OS in LABC patients, compared with the triweekly ET combination, and the therapeutic advantage is limited to patients with highly aggressive tumours.
Preoperative weekly cisplatin-epirubicin-paclitaxel with G-CSF support in triple-negative large operable breast cancer.
Eight weekly PET cycles are a highly effective primary treatment in women with triple-negative large operable breast cancer and results in a very promising long-term DFS in this poor prognosis population.
Higher rate of skin rash in a phase II trial with weekly nanoparticle albumin-bound paclitaxel and cisplatin combination in Chinese breast cancer patients
A higher rate of maculo-papular rash occurred in Chinese breast cancer patients treated with weekly nab-paclitaxel compared to western patients, suggesting the albumin component of nab- paclitaxe might be the cause of the skin disorder.
Cisplatin improves antitumor activity of weekly nab-paclitaxel in patients with metastatic breast cancer
Efficacy of weekly nab-paclitaxel can be improved by adding cisplatin, with quick response, manageable toxicity, and possible equivalence across molecular subtypes in MBC patients.
Weekly TP regimen as a postoperative adjuvant chemotherapy for completely resected breast cancer in China: final result of a phase II trial.
WTP is safe and effective at the doses tested, however, a randomized clinical trial is needed to compare wTP with other conventional adjuvant regimens of breast cancer postoperatively.
Weekly Cisplatin plus Capecitabine in Metastatic Breast Cancer Patients Heavily Pretreated with both Anthracycline and Taxanes
The cisplatin and capecitabine combination regimen is active and manageable and seems to be non-cross resistant to anthracycline- and taxane-pretreated metastatic breast cancer.
A 2-month cisplatin-epirubicin-paclitaxel (PET) weekly combination as primary systemic therapy for large operable breast cancer: a phase II study.
A 2-month weekly treatment with PET represents a well tolerated and highly effective approach in large operable breast cancer patients, and in spite of the short duration of chemotherapy, one-third of patients achieved a complete eradication of the tumor in both breast and axilla.
Low dose Gemcitabine plus cisplatin in a weekly-based regimen as salvage therapy for relapsed breast cancer after taxane-anthracycline-containing regimens
An exploratory study to determine if treatment with low doses of a combination of fixed-rate gemcitabine infusion and cisplatin was clinically meaningful in women relapsing after a minimum of 2 prior lines of CT for advanced disease.
Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel
Preoperative cisplatin containing chemotherapy followed by paclitaxel induced an high pCR rate in a population of triple-negative breast cancer, and the impact of this schedule on long-term outcome should be investigated in larger series.